ALP was founded as a lipid and medical biochemistry research company in 2008 to specifically advance new research in the area of fatty liver disease and related lipid metabolism. Fatty liver disease is an emerging global epidemic in both the developed and emerging world. ALP research is focused on novel nutritional based methods of addressing the growing evidence of the connection between chronic inflammatory diseases and various stages of fatty liver disease. The ALP mission is to conduct lipid research and offer or license new products addressing chronic inflammatory diseases, and provide nutritional medicine based education to physicians and patients. The emerging science of Applied Lipid Polymorphism “ALP” is simply the use of appropriate doses of formulated lipids as nutritional medicine and packaged as Rx, medical food or OTC products to facilitate the remodeling of lipids in the human body to optimize human health. The ALP mission in research and development is to create nutritional medicine products that utilize newly discovered medical biochemistry to trigger the anti-inflammatory clinical response in the patient.